share_log
Reuters ·  Apr 30 08:00
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (Ux143) for the Treatment of Osteogenesis Imperfecta (Oi)
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment